Pulmonary Tumor Thrombotic Microangiopathy Suspected to be COVID-19 Vaccine-Related Myocarditis: A Case Report
Open Access
- 24 March 2024
- journal article
- research article
- Published by Springer Nature in Cureus
- Vol. 16 (3) , e56803
Abstract
Pulmonary tumor thrombotic microangiopathy (PTTM) is a very rare condition that can lead to acute severe pulmonary hypertension and circulatory failure. It is caused by tumor cell microvascular obstruction and is usually difficult to diagnose; in fact, it is often diagnosed after death. We report the case of a patient who experienced a sudden cardiac arrest and developed severe pulmonary hypertension two days after receiving the coronavirus disease (COVID-19) vaccine. The patient was initially diagnosed with vaccine -associated myocarditis, and venoarterial extracorporeal membrane oxygenation (VA-ECMO) implantation with median sternotomy was performed. The patient survived for more than two weeks. PTTM was later diagnosed during a pathological autopsy.Keywords
This publication has 6 references indexed in Scilit:
- Pulmonary Tumor Thrombotic Microangiopathy as a Cause of Pulmonary HypertensionJACC: Case Reports, 2021
- Pulmonary tumor thrombotic microangiopathy: a systematic reviewPulmonary Circulation, 2019
- Flow mixing during peripheral veno-arterial extra corporeal membrane oxygenation – A simulation studyJournal of Biomechanics, 2017
- Pulmonary Tumor Thrombotic Microangiopathy: A Clinical Analysis of 30 Autopsy CasesInternal Medicine, 2013
- Small cell carcinoma of the liver and biliary tract without jaundiceWorld Journal of Gastroenterology, 2013
- Pulmonary tumor embolism: a review of the literatureThe American Journal of Medicine, 2003